# Metabolic & Weight Loss Peptides

## Overview

Metabolic peptides support fat loss, glucose control, and appetite regulation through incretin receptor signaling, lipolytic pathways, and metabolic enzyme modulation.

## Quick Reference

| Product | Size | Risk | Best For |
|---------|------|------|----------|
| RTA | 5mg | Moderate | Triple GLP-1/GIP/Glucagon metabolic optimization |
| Semaglutide | 5mg | Moderate | GLP-1 receptor agonist; fat loss + glucose control |
| Tirzepatide | 5mg | Moderate | Dual GLP-1/GIP incretin signaling |
| Mazdutide | 5mg | Moderate | Dual GLP-1/Glucagon agonist |
| Cagrilintide | 5mg | Moderate | Amylin receptor agonist; appetite suppression |
| Sema + Cagri Blend | 5mg + 5mg | Moderate | Combined metabolic support |
| AOD-9604 | 5mg | Low-Moderate | Direct fat mobilization |
| 5-Amino-1MQ | — | Low-Moderate | NNMT inhibition; metabolic enhancement |

## Key Compounds

### Retatrutide (RTA)
- **Primary Targets**: GLP1R + GIPR + Glucagon receptor (GCGR)
- **Pathways**:
  - ↑ Energy expenditure (via GCGR)
  - ↑ Lipolysis
  - ↑ Insulinotropic signaling
  - ↑ Hepatic fat oxidation
- **Typical Use**: 1–12mg weekly (slow titration)
- **Route**: Subcutaneous
- **Duration**: Ongoing (titrate based on tolerance and goals)
- **Notes**: Most potent metabolic compound available; up to 24% body weight reduction in clinical trials. CULTR's primary GLP recommendation.

### Semaglutide
- **Primary Target**: GLP-1 receptor (GLP1R; Gs-coupled GPCR)
- **Pathways**:
  - ↑ cAMP → PKA activation
  - ↑ Insulin secretion (glucose-dependent)
  - ↓ Glucagon
  - Delayed gastric emptying
  - CNS satiety signaling (hypothalamus)
- **Typical Use**: 0.25–2.4mg weekly (slow titration)
- **Half-life**: 7 days
- **Route**: Subcutaneous
- **Duration**: Ongoing

### Tirzepatide
- **Primary Targets**: GLP1R + GIP receptor (GIPR)
- **Pathways**:
  - Dual incretin signaling
  - ↑ β-cell insulinotropic response
  - ↑ Adipocyte insulin sensitivity
  - Enhanced metabolic flexibility
- **Typical Use**: 2.5–15mg weekly (slow titration)
- **Half-life**: 5 days
- **Route**: Subcutaneous
- **Duration**: Ongoing
- **Best For**: Dual-pathway metabolic optimization

### Mazdutide
- **Primary Targets**: GLP1R + Glucagon receptor
- **Pathways**:
  - ↑ Energy expenditure
  - ↑ Weight reduction via dual mechanism
  - Hepatic metabolic modulation
- **Route**: Subcutaneous
- **Duration**: Ongoing
- **Best For**: Dual-agonist metabolic support

### Cagrilintide
- **Primary Target**: Amylin receptor
- **Pathways**:
  - Delayed gastric emptying
  - ↑ CNS satiety signaling
  - Dual GI/CNS appetite suppression
- **Typical Use**: 0.25–2.4mg weekly (slow titration)
- **Route**: Subcutaneous
- **Duration**: Ongoing (titrate based on tolerance)
- **Notes**: Emerging compound with strong appetite suppression

### Semaglutide + Cagrilintide Stack
- **Combined Mechanism**: GLP-1 agonist + Amylin agonist for enhanced metabolic effect
- **Pathways**:
  - Dual receptor activation (GLP1R + Amylin)
  - ↑ Insulin secretion + ↑ Satiety
  - ↓ Glucagon + Delayed gastric emptying
- **Typical Use**: Semaglutide 0.25–2.4mg weekly + Cagrilintide 0.25–2.4mg weekly (titrate slowly)
- **Route**: Subcutaneous
- **Duration**: Ongoing
- **Best For**: Significant weight loss goals
- **Note**: RTA is the preferred primary GLP compound; this combination is an alternative approach

### AOD-9604
- **Primary Target**: Fragment of GH (176–191 region)
- **Receptor Interaction**: Weak GH receptor activity (non-growth signaling)
- **Downstream Effects**:
  - ↑ Lipolysis (HSL activation)
  - ↓ Lipogenesis
  - Limited IGF-1 stimulation
- **Typical Use**: 250–500mcg daily
- **Half-life**: 1–2 hours
- **Route**: Subcutaneous
- **Duration**: 8–12 weeks
- **Unique**: Targeted fat reduction without systemic HGH effects

### 5-Amino-1MQ
- **Primary Target**: NNMT (Nicotinamide N-methyltransferase) inhibition
- **Downstream Effects**:
  - ↑ NAD+ salvage pathway flux
  - ↑ SIRT1 activity (indirect)
  - ↑ Mitochondrial biogenesis signaling
  - ↑ AMPK activation
  - Improved adipocyte metabolic signaling
- **Best For**: Body recomposition via metabolic pathway enhancement

## Optimal Timing Guide

| Product | Optimal Timing | Notes |
|---------|---------------|-------|
| RTA | Morning or consistent daytime | Metabolic consistency |
| Semaglutide | Same day each week | Weekly injection; consistency critical |
| Tirzepatide | Same day each week | Weekly injection; consistent timing |
| Mazdutide | Same day each week | Weekly injection; consistent timing |
| Cagrilintide | Same day each week | Weekly injection; pick consistent day/time |
| AOD-9604 | Morning (fasted) or pre-cardio | Empty stomach 2–3 hours before/after |
| 5-Amino-1MQ | Morning | Metabolic activation; fasted preferred |

**Key Rules**:
- **GLP-1 weekly injections (RTA, Semaglutide, Tirzepatide, Mazdutide)**: Same day and time every week; set a recurring reminder
- **Fat-loss peptides (AOD-9604, 5-Amino-1MQ)**: Fasted morning or 2–3 hours after last meal
- **Hydration**: GI side effects from GLP-1 agonists require adequate hydration throughout day

## Metabolic Optimization Protocols

### Conservative Approach (Weight Maintenance + Body Recomposition)
- Cagrilintide: 0.25mg weekly (titrate as needed)
- AOD-9604: 250mcg daily (fasted)
- Lifestyle: Caloric balance with protein emphasis
- Duration: 8–12 weeks

### Aggressive Fat Loss (Deficit-Based)
- RTA: 1–12mg weekly (titrate as tolerated) — primary GLP compound
- Cagrilintide: 0.25–0.5mg weekly (optional add-on)
- Caloric deficit: 300–500 kcal/day
- Protein: 1g per lb body weight

### Metabolic Enhancement (Non-GLP-1)
- 5-Amino-1MQ: Daily (NNMT inhibition for NAD+ flux)
- AOD-9604: 250–500mcg daily (lipolysis support)
- Best For: Those seeking metabolic improvement without incretin-class compounds

## Safety Considerations

- **Nausea**: Common with GLP-1 agonists; subsides with time and slow titration
- **Dehydration**: Maintain excellent hydration
- **Blood Sugar**: Monitor glucose, especially if diabetic
- **Thyroid**: Watch for thyroid C-cell effects (from preclinical data)
- **Titration**: All incretin-class compounds require slow dose escalation

## Disclaimer

This information is for research purposes only. Not approved for human consumption in most jurisdictions. Consult healthcare providers before use.
